Encompass Health Corporation EHC
Composite 59/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 40/100 — a slight mark against it.
Quality ranks 72/100 — a moderate point in its favour. Balance-sheet strength ranks 61/100 — a slight point in its favour. Momentum ranks 58/100 — a slight point in its favour.
Income ranks 40/100 — a slight mark against it. Valuation ranks 48/100 — a slight mark against it.
What the company does Encompass Health operates 150+ inpatient rehab hospitals in the U.S. and Puerto Rico, serving Medicare, managed care, and private-pay patients recovering from strokes, injuries, and surgeries.
Key financials ROE 25.2%, ROA 9.7%, ROCE 17.5%; gross/operating/net margins 43.5%/19.0%/10.0%. Revenue grew 9.0% and EPS 30.3%, with strong cash generation (FCF yield 2.6%).
Stock health Sideravia scores: Quality 69.5, Growth 61.0, Strength 62.2, Valuation 58.0, Momentum 50.2, Income 49.0. Profitability metrics and F-Score 8/9 signal operational strength.
Price vs fair value The stock trades at a PREMIUM of 38.50% to our fair-value estimate and a discount of 26.70% to the 12-month target. - Trading at a premium to fair value (Sideravia) - Discount to analyst target (12.0 analysts) - Valuation percentile 58.0/100 (Sideravia) - Forward P/E 18.83 vs trailing 19.33 (Valuation)
Looking forward Forward PEG 7.12 suggests high growth expectations; momentum is mixed with 12m +3.16% but -12.87% from the 52w high. Execution on growth and margin stability will drive re-rating.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.